• 5027 Citations
  • 39 h-Index
If you made any changes in Pure these will be visible here soon.

Personal profile


Dr Creaney is the Head of the Biomarkers and Discovery unit of NCARD. The group is investigating biomarkers for improved diagnosis and monitoring of patients with mesothelioma and also examining the use of biomarkers for screening asbestos-exposed individuals for early detection of mesothelioma.
Jenette received her PhD in 1995 from La Trobe University (Melbourne, Australia), and has worked in the cancer and immunology fields as a molecular biologist and protein chemist since. Jenette returned to Australia from the US in 1999 to work with Professor Bruce Robinson in Perth, on principally the marker discovery projects. The work from the group includes the seminal work on the biomarker mesothelin for use in patients with mesothelioma.
Jenette has received several prestigious awards for her work in Science including the Howard Hughes Medical Institute Postdoctoral Fellowship and a Young Investigator Award.


Mesothelin – a tumour associated antigen for mesothelioma
Biomarkers for determination of drug sensitivity in mesothelioma
Next generation sequencing for malignant mesothelioma and lung cancer
Tumour immunology


  • Cancer immunology

Fingerprint Dive into the research topics where Jenette Creaney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 49 Similar Profiles
Mesothelioma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Asbestos Medicine & Life Sciences
Genes Chemical Compounds
Tumors Chemical Compounds
Atlases Medicine & Life Sciences
Pleural Effusion Medicine & Life Sciences
Genome Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

1 Citation (Scopus)

Advances in pathological diagnosis of mesothelioma: what pulmonologists should know

Louw, A., Badiei, A., Creaney, J., Chai, M. S. & Lee, Y. C. G., 1 Jul 2019, In : Current Opinion in Pulmonary Medicine. 25, 4, p. 354-361 8 p.

Research output: Contribution to journalArticle

BRCA1 Protein
Cyclin-Dependent Kinase Inhibitor p16
Fluorescence In Situ Hybridization
Developing Countries
1 Citation (Scopus)

Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life

Jeffery, E., Lee, Y. C. G., Newton, R. U., Lyons-Wall, P., McVeigh, J., Nowak, A. K., Cheah, H. M., Nguyen, B., Fitzgerald, D. B., Creaney, J., Straker, L. & Peddle-McIntyre, C. J., 1 Oct 2019, In : European Journal of Clinical Nutrition. 73, 10, p. 1412-1421 10 p.

Research output: Contribution to journalArticle

Body Composition
Nutritional Status
Quality of Life

Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma

Sneddon, S., Rive, C. M., Ma, S., Dick, I. M., Allcock, R. J. N., Brown, S. D., Holt, R. A., Watson, M., Leary, S., Lee, Y. C. G., Robinson, B. W. S. & Creaney, J., 1 Jan 2019, In : OncoImmunology. 1684713.

Research output: Contribution to journalArticle

Open Access
Pleural Effusion
4 Citations (Scopus)

Immunotherapy strategies for mesothelioma–the role of tumor specific neoantigens in a new era of precision medicine

Ye, L., Ma, S., Robinson, B. W. & Creaney, J., 1 Feb 2019, In : Expert Review of Respiratory Medicine. 13, 2, p. 181-192 12 p.

Research output: Contribution to journalReview article

Precision Medicine

Malignant Pleural Mesothelioma: an Update for Pulmonologists

Sidhu, C., Louw, A., Brims, F., Creaney, J. & Lee, Y. C. G., Jun 2019, In : Current Pulmonology Reports. 8, 2, p. 40-49 10 p.

Research output: Contribution to journalArticle

Projects 2001 2021